UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000038219 |
|---|---|
| Receipt number | R000043549 |
| Scientific Title | Expression of Vasohibin Family in Gastric Carcinoma. |
| Date of disclosure of the study information | 2019/10/07 |
| Last modified on | 2019/10/07 12:14:04 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Expression of Vasohibin Family in Gastric Carcinoma.
Acronym
Expression of Vasohibin Family in Gastric Carcinoma.
Scientific Title
Expression of Vasohibin Family in Gastric Carcinoma.
Scientific Title:Acronym
Expression of Vasohibin Family in Gastric Carcinoma.
Region
| Japan |
Condition
Condition
Gastric Cancer
Classification by specialty
| Surgery in general | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The purpose is to investigate the immunohistochemical expression of Vasohibin-1 and Vasohibin-2 in gastric cancer.
Basic objectives2
Others
Basic objectives -Others
The purpose is to investigate the relationship between Vasohibin-1 and Vasohibin-2 immunohistochemical expression and clinicopathological significance and prognosis in gastric cancer.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The primary outcomes are to evaluate immunohistochemical expressions of Vasohibin-1 and Vasohibin-2 in gastric cancer and to investigate their clinicopathological significance.
Key secondary outcomes
The secondary outcomes are to examine the relationship between Vasohibin-1 and Vasohibin-2 immunohistochemical expression in gastric cancer, and to examine the relationship between the respective expression status and prognosis.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Gastric cancer patients who underwent radical surgery at Tokai University Hospital from January 2009 to December 2013.
Key exclusion criteria
Patients who were previously treated for cancers, residual, multiple, pT1a, or stage IV cancers, or multiple primary cancers with other tumors were excluded from our study.
Target sample size
210
Research contact person
Name of lead principal investigator
| 1st name | Ozawa |
| Middle name | |
| Last name | Soji |
Organization
Tokai University School of Medicine
Division name
Department of Gastroenterological Surgery
Zip code
2591193
Address
143 Shimokasuya, Isehara, Kanagawa
TEL
0463931121
sozawa@tokai.ac.jp
Public contact
Name of contact person
| 1st name | Hara |
| Middle name | |
| Last name | Hitoshi |
Organization
Tokai University School of Medicine
Division name
Department of Gastroenterological Surgery
Zip code
2591193
Address
143 Shimokasuya, Isehara, Kanagawa
TEL
0463931121
Homepage URL
h-hara@is.icc.u-tokai.ac.jp
Sponsor or person
Institute
Department of Gastroenterological Surgery, Tokai University School of Medicine,
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Tokai University School of Medicine, IRB
Address
143 Shimokasuya, Isehara, Kanagawa
Tel
0463931121
h-hara@is.icc.u-tokai.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 10 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
210
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2017 | Year | 07 | Month | 11 | Day |
Date of IRB
| 2017 | Year | 07 | Month | 11 | Day |
Anticipated trial start date
| 2017 | Year | 07 | Month | 11 | Day |
Last follow-up date
| 2018 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
We aimed to assess vasohibins expression in gastric cancer and their effect on patient prognosis. We examined 210 gastric cancer patients who underwent radical surgery at Tokai University Hospital from January 2009 to December 2013. We performed immunohistochemistry using anti-VASH1 and anti-VASH2 antibodies and examined vasohibins expression. Patients were categorized into VASH1-positive and VASH1-negative groups and high and low VASH2 expression groups to retrospectively investigate clinicopathological factors and prognosis.
Management information
Registered date
| 2019 | Year | 10 | Month | 07 | Day |
Last modified on
| 2019 | Year | 10 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043549
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
